1. What is it?
DSIP is a short peptide made of nine amino acids. FDA documents also use the name emideltide. Delta refers to waves seen in recordings of brain activity during deep sleep. The name reflects the direction of early research, but does not itself prove that a medicine works. The description of a specific molecule must also be distinguished from its salts and other derivatives, because similar naming does not guarantee that every preparation is identical. [92]
2. Why do people turn to it?
People interested in DSIP usually hope to fall asleep more easily, sleep more peacefully and feel more rested in the morning. These are understandable aims, but not all have been convincingly confirmed. Studies have examined chronic insomnia, while much weaker reports have also looked at narcolepsy and opioid withdrawal symptoms. These are not interchangeable problems. Improvement in one sleep recording does not establish a treatment for every cause of fatigue, just as a report about one patient does not establish effectiveness for a condition as a whole. [90] [91] [92]
3. How does it work?
There is no basis for presenting DSIP as a simple switch for deep sleep. Researchers examined different aspects of sleep: time to fall asleep, sleep duration, awakenings and daytime functioning. Their tools included polysomnography, which records brain activity and other signals simultaneously overnight. Such measurements help distinguish the feeling of better sleep from a measurable change. Confirmation is still needed that any change is large enough, lasting and noticeable to the patient. [90] [91]
4. What do studies actually show?
A 1987 paper involved 14 people with chronic insomnia and described improved sleep and daytime functioning during short treatment. A 1992 study reached much more cautious conclusions. Despite changes in some measurements, its authors considered the effects weak, and overall subjective sleep quality did not improve. They concluded that short treatment with DSIP was unlikely to offer a substantial therapeutic benefit. These conflicting findings need to be presented together. [90] [91]
5. What do we still not know?
The sleep studies involved few people and short follow-up periods, with methods varying between papers. The FDA also identified problems with the choice of comparisons and uncertainty about the importance of some findings for patients. Most of the reported experiments used intravenous administration. They do not establish the effectiveness of the subcutaneous form considered by the regulator. Practical questions remain unanswered: does improvement last for months, do people function better, and do benefits outweigh adverse effects? [92]
6. What are the risks?
Some small studies described good tolerability, but they are not sufficient to detect rare or delayed problems. The FDA also discussed reports of low blood pressure, nausea, sweating and dizziness in people treated for withdrawal symptoms. Their condition makes it difficult to assess what the peptide actually caused. Separate concerns involve immune reactions and substance quality. Without a well-established rate of complications, DSIP cannot be described as risk-free. [92]
7. Is it an approved medicine?
There is no basis here for presenting DSIP to Polish readers as a proven insomnia medicine. Sources used for this profile did not confirm Polish authorization. In July 2026 materials, the FDA noted that the assessed forms were not ingredients in an FDA-approved medicine. The meeting concerned US compounding rules. Committee consideration and opinion are not treatment approval. [92] [93]
8. What is new in research?
The main update is the FDA assessment presented in July 2026. After reviewing older experiments, the regulator considered the findings for chronic insomnia inconclusive and preliminary, and found no evidence supporting the effectiveness of the proposed subcutaneous administration. This is a current assessment of earlier research, not a new patient study. By 3 November 2026, no large new trial had been found that resolved these issues and justified stronger promises of better sleep. [92]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
1987; small primary study in people with chronic insomnia; PubMed metadata and English abstract read, without the full text · DOI: 10.1159/000116143. Accessed: 03.11.2026.
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
1992; primary small double-blind study in people with chronic insomnia; PubMed metadata and English abstract reviewed, not the full text · DOI: 10.1159/000118919. Accessed: 3 November 2026.
- July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting
FDA, presentations on 24.07.2026; sections on emideltide/DSIP were read: identity, insomnia, narcolepsy, opioid withdrawal, safety and conclusions. Other substances in the presentations were not assessed. Accessed: 03.11.2026.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
FDA, 23–24 July 2026; agenda, explanation of the committee's advisory role and document list reviewed. Accessed: 3 November 2026.